Basic Information
| ID | DRAMP21370 |
|---|
| Sequence | FLKALWNVAKKVF |
|---|
| Length | 13 |
|---|
| Name | [Lys]3[Lys]11-VmCT1-NH2 (Derived from VmCT1) |
|---|
| Source | synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal |
|---|
| Pathogen | [Ref.31181304] Gram-positive bacteria: Micrococcus luteus A270 (MIC=0.4 μmol/L), Staphylococcus aureus ATCC 29213 (MIC=0.8 μmol/L), Bacillus megaterium ATCC 10778 (MIC=0.4 μmol/L), Staphylococcus epidermidis ATCC 12228 (MIC=1.6 μmol/L);##Gram-negative bacteria: Escherichia coli SBS 363 (MIC=1.6 μmol/L)，Serratia marcescens ATCC 4112 (MIC=0.2 μmol/L), Enterobacter cloacae β-12 (MIC=3.1 μmol/L);##Fungi: Candida albicans MDM8 (MIC=1.6 μmol/L), Candida tropicalis IOC 4560 (MIC=0.4 μmol/L) |
|---|
| Hemolytic Activity | [Ref.31181304] 40% hemolysis at 12.5 μmol/L, 70% hemolysis at 25 μmol/L, 80% hemolysis at 50 μmol/L against human red blood cells |
|---|
| Cytotoxicity | [Ref.31181304] ①The cell viability of MCF-7 cells induced by [Lys3][Lys11]-VmCT1-NH2 is 95%, 100%, 80%, 80%, 55%, 45%, 20% and 20% at peptide concentrations of 0.8, 1.6, 3.1, 12.5, 25, 50 and 100 μM. ②The cell viability of MCF-10A cells induced by [Lys3][Lys11]-VmCT1-NH2 is 120%, 120%, 90%, 100%, 120% and 95% at peptide concentrations of 0.8, 1.6, 3.1, 6.3, 12.5 and 25 μM. |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 31181304 |
|---|
